ProMIS Neurosciences Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(expressed in US dollars)


· · Six Months Ended ·
· · June 30, ·
· · 2026 · · 2025 ·
Cash flows from operating activities
Net loss	$(19,974,029)	$(17,464,932)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	598,319	457,310
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(231,120)	620,912
Accounts payable	(749,940)	1,042,716
Accrued liabilities	(2,411,815)	6,562,946
Net cash used in operating activities	(22,768,585)	(8,781,048)

Cash flows from financing activities
Proceeds from issuance of Common Shares, pre-funded warrants, and common warrants from January 29, 2026 PIPE, net of issuance costs	70,081,309	—
Net cash provided by financing activities	70,081,309	—

Net increase (decrease) in cash	47,312,724	(8,781,048)

Cash at beginning of period	6,116,556	13,291,167
Cash at end of period	$53,429,280	$4,510,119

Noncash financing activities
Increase (decrease) in share-based compensation liability on C$ denominated share options decreasing (increasing) additional paid-in-capital	$48,073	$(136,868)
Deferred financing costs reclassified to additional paid-in capital upon completion of equity financing	$32,332	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.